BioSpace News Archive

ACELYRIN, INC. announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction.

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, announced a clinical trial collaboration and supply agreement with Merck.

Remix Therapeutics, a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, announced the appointment of Christopher Bowden, M.D., as Chief Medical Officer.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of its management team in a virtual press conference launching the annual UNESCO Week of Sound, an event sponsored by Sensorion, on January 10, 2023.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that Juliet Thompson has been appointed as a Non-Executive Director of the Company, with effect from 5 January 2023.

MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.

NRx Pharmaceuticals, Inc. announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.

Ryvu Therapeutics announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® Panel Discussion entitled “European Partners Dream Big, Make Bold Progress” on Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time.

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, announced that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023.

IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced a clinical update from the ongoing Phase 1 trial evaluating INB-200 in patients with newly diagnosed GBM and provided pipeline goals for 2023.